drugset / Trial / NCT01183884
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
Timeline
- Start
- 2010-08
- Primary completion
- 2018-11-09
- Completion
- 2018-11-09
Outcome
Outcome not reported
Stopped (Enrollment): “Low participant accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 13-cis-retinoic acid | Unknown | — | — |
| Subject | 3F8 | Monoclonal antibody | 20 mg/m2 | — |
| Subject | GM-CSF | Protein / enzyme biologic | — | — |